132 related articles for article (PubMed ID: 21610150)
1. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
2. B-cell receptor signaling in diffuse large B-cell lymphoma.
Young RM; Shaffer AL; Phelan JD; Staudt LM
Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
[TBL] [Abstract][Full Text] [Related]
3. Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.
Gamboa-Cedeño AM; Castillo M; Xiao W; Waldmann TA; Ranuncolo SM
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1437-1448. PubMed ID: 30941572
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release.
Hussain AR; Uddin S; Ahmed M; Al-Dayel F; Bavi PP; Al-Kuraya KS
PLoS One; 2013; 8(3):e60540. PubMed ID: 23555990
[TBL] [Abstract][Full Text] [Related]
5. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.
Li MY; Chong LC; Duns G; Lytle A; Woolcock B; Jiang A; Telenius A; Ben-Neriah S; Nawaz W; Slack GW; Elisia I; Viganò E; Aoki T; Healy S; Krystal G; Venturutti L; Scott DW; Steidl C
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2320421121. PubMed ID: 38662551
[TBL] [Abstract][Full Text] [Related]
6. Use of cell permeable NBD peptides for suppression of inflammation.
Strickland I; Ghosh S
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii75-82. PubMed ID: 17038479
[TBL] [Abstract][Full Text] [Related]
7. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).
Kim PM; Nejati R; Lu P; Thakkar D; Mackrides N; Dupoux V; Nakhoda S; Baldwin DA; Pei J; Dave SS; Wang YL; Wasik MA
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37730436
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of ENKD1 disrupts cellular homeostasis to promote lymphoma development.
Song T; He N; Hao Z; Yang Y
J Cell Physiol; 2023 Jun; 238(6):1308-1323. PubMed ID: 36960713
[TBL] [Abstract][Full Text] [Related]
9. Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma.
Schnorenberg MR; Hawley KM; Thomas-Toth AT; Watkins EA; Tian Y; Ting JM; Leak LB; Kucera IM; Raczy MM; Kung AL; Hubbell JA; Tirrell MV; LaBelle JL
ACS Nano; 2023 Dec; 17(23):23374-23390. PubMed ID: 37688780
[TBL] [Abstract][Full Text] [Related]
10. Parthenolide As a Therapeutic for Disseminated Canine Neoplasms.
Schlein LJ; Brill SA; Brady RV; Farrell KB; Rose BJ; Meuten TK; Jordan CT; Thamm DH
J Pharmacol Exp Ther; 2024 Feb; 388(3):774-787. PubMed ID: 38135509
[TBL] [Abstract][Full Text] [Related]
11. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
Jeon MJ; Yu ES; Choi CW; Kim DS
Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
[TBL] [Abstract][Full Text] [Related]
12. Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma.
Liu B; Zhao X; Zhang S; Li Q; Li X; Huang D; Xia J; Ma N; Duan Y; Zhang X; Rao J
Leukemia; 2024 Feb; 38(2):351-364. PubMed ID: 38195819
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation.
Wu Y; Chang YM; Polton G; Stell AJ; Szladovits B; Macfarlane M; Peters LM; Priestnall SL; Bacon NJ; Kow K; Stewart S; Sharma E; Goulart MR; Gribben J; Xia D; Garden OA
Front Oncol; 2020; 10():307. PubMed ID: 32211332
[TBL] [Abstract][Full Text] [Related]
14. Mediation of Ferroptosis Suppressor Protein 1 Expression via 4-Hydroxy-2-Nonenal Accumulation Contributes to Acquisition of Resistance to Apoptosis and Ferroptosis in Diffuse Large B-Cell Lymphoma.
Kawade G; Kurata M; Matsuki Y; Fukuda S; Onishi I; Kinowaki Y; Watabe S; Ishibashi S; Ikeda M; Yamamoto M; Ohashi K; Kitagawa M; Yamamoto K
Lab Invest; 2024 Apr; 104(4):102027. PubMed ID: 38311062
[TBL] [Abstract][Full Text] [Related]
15. Mouse models of diffuse large B cell lymphoma.
Tabatabai A; Arora A; Höfmann S; Jauch M; von Tresckow B; Hansen J; Flümann R; Jachimowicz RD; Klein S; Reinhardt HC; Knittel G
Front Immunol; 2023; 14():1313371. PubMed ID: 38124747
[TBL] [Abstract][Full Text] [Related]
16. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
Leuk Lymphoma; 2024 Mar; ():1-16. PubMed ID: 38497543
[TBL] [Abstract][Full Text] [Related]
17.
Kalac M; Mangone M; Rinderspacher A; Deng SX; Scotto L; Markson M; Bansal M; Califano A; Landry DW; O'Connor OA
iScience; 2020 Dec; 23(12):101884. PubMed ID: 33354662
[TBL] [Abstract][Full Text] [Related]
18. XPO1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive Lymphoma.
Knittel G; Reinhardt HC
Cancer Res; 2024 Jan; 84(1):3-5. PubMed ID: 37902414
[TBL] [Abstract][Full Text] [Related]
19. Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.
Bhalla K; Jaber S; Nahid M N; Underwood K; Beheshti A; Landon A; Bhandary B; Bastian P; Evens AM; Haley J; Polster B; Gartenhaus RB
Sci Rep; 2018 Jan; 8(1):744. PubMed ID: 29335581
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma.
Plotnik JP; Richardson AE; Yang H; Rojas E; Bontcheva V; Dowell C; Parsons S; Wilson A; Ravanmehr V; Will C; Jung P; Zhu H; Partha SK; Panchal SC; Mali RS; Kohlhapp FJ; McClure RA; Ramathal CY; George MD; Jhala M; Elsen NL; Qiu W; Judge RA; Pan C; Mastracchio A; Henderson J; Meulbroek JA; Green MR; Pappano WN
Mol Cancer Ther; 2024 Mar; ():. PubMed ID: 38507740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
